Free Trial

NovoCure (NVCR) Earnings Date, Estimates & Call Transcripts

NovoCure logo
$23.67 -0.08 (-0.34%)
Closing price 02/4/2025 04:00 PM Eastern
Extended Trading
$23.68 +0.00 (+0.02%)
As of 02/4/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 27Before Market OpensEstimated
Actual EPS
(Oct. 30)
-$0.28 Beat By $0.06
Consensus EPS
(Oct. 30)
-$0.34

NovoCure announced Q3 2024 earnings on October 30, 2024, reporting an EPS of -$0.28, which topped the consensus estimate of -$0.34 by $0.06. Quarterly revenue rose 21.8% year-over-year to $155.10 million, above analysts' expectations of $143.95 million. With a trailing EPS of -$1.40, NovoCure's earnings are expected to decrease next year, from ($1.30) to ($1.72) per share.

NVCR Upcoming Earnings

NovoCure's next earnings date is estimated for Thursday, February 27, 2025, based off prior year's reporting schedules, with a conference call scheduled for at 8:00 AM ET. Interested parties can register for or listen to the call.

Get NovoCure Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NovoCure and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

NVCR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

NVCR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

NovoCure Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20252-$0.45-$0.32-$0.39
Q2 20252-$0.48-$0.35-$0.42
Q3 20252-$0.52-$0.38-$0.45
Q4 20252-$0.57-$0.39-$0.48
FY 20258($2.02)($1.44)($1.73)

NovoCure Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
2/27/2025
(Estimated)
-------
10/30/2024Q3 2024-$0.34-$0.28+$0.06-$0.28$143.95M$155.10M
7/25/2024Q2 2024-$0.40-$0.31+$0.09-$0.31$135.83M$150.40M
5/2/2024Q1 2024-$0.43-$0.36+$0.07-$0.36$131.44M$138.50M
2/22/2024Q4 2023-$0.53-$0.45+$0.08-$0.45$133.80M$133.80M
10/26/2023Q3 2023-$0.51-$0.46+$0.05-$0.46$128.75M$127.30M
7/27/2023Q2 2023-$0.50-$0.54 -$0.04-$0.54$124.25M$126.05M
5/4/2023Q1 2023-$0.36-$0.50 -$0.14-$0.50$127.93M$122.20M
2/23/2023Q4 2022-$0.32-$0.36 -$0.04-$0.36$127.20M$128.43M

NovoCure Earnings - Frequently Asked Questions

NovoCure has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates. Learn more on NVCR's earnings history.

NovoCure updated its FY 2024 earnings guidance on Monday, January, 13th. The company issued revenue guidance of $605.0 million-$605.0 million, compared to the consensus revenue estimate of $597.0 million.

In the previous quarter, NovoCure (NASDAQ:NVCR) reported ($0.28) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.34) by $0.06. Learn more on analysts' earnings estimate vs. NVCR's actual earnings.

The conference call for NovoCure's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for NovoCure's latest earnings report can be read online.
Read Transcript

NovoCure's earnings report can be found in their filing with the SEC.
View SEC filing

NovoCure (NASDAQ:NVCR) has a recorded annual revenue of $509.34 million.

NovoCure (NASDAQ:NVCR) has a recorded net income of -$207.04 million. NVCR has generated -$1.40 earnings per share over the last four quarters.

NovoCure's earnings are expected to decrease from ($1.30) per share to ($1.72) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:NVCR) was last updated on 2/5/2025 by MarketBeat.com Staff
From Our Partners